VHH Case Studies
Our case studies highlight how VHH technology is addressing complex challenges across industries such as biotechnology and pharmaceuticals. See how leading organisations are applying VHHs to advance research and develop novel solutions.
Retaining binding characteristics and strong biophysics during VHH humanisation
Humanising an immune-derived VHH can increase human-likeness but may compromise affinity or developability. This case study shows how Isogenica combined bioinformatics, structural insight and iterative experimental testing to generate humanised variants that retained binding affinity and favourable biophysical properties.
Specific Antibodies to Difficult Targets: How to find the needles in the haystack
Peptides, often small and unstructured, are some of the most difficult targets in antibody discovery. Here, we recount how we tweaked our approach to mining our vast VHH libraries to isolate highly specific binders for difficult targets like these, even when other methods had failed.
‘Intrabodies’ – Isogenica’s VHH antibodies improve heart function when delivered intracellularly
Our VHH antibodies have been put to the test as a potential new therapy for heart failure in an early-stage study from AstraZeneca published in Nature Communications. In a step forward for intracellular biotherapeutics, this early stage investigational research also used a viral vector to deliver our VHH antibodies directly inside heart cells
Unlocking Affordable Biologics: VHH Antibodies in Baker’s Yeast
The production of traditional IgG monoclonal antibodies has long been hindered by their complexity. These molecules require complex and costly manufacturing processes, with estimated production costs ranging from $95 to $200 per gram.
Tools for ADC drug discovery – screening VHHs with pre-engineered C-terminal cysteine handles
In the fast-paced world of biotechnology, innovation often stems from taking smart, calculated risks. At Isogenica, we are used to running unusual antibody drug discoveryprojects. But sometimes, even we have our doubts. One such moment arose when several Antibody-Drug Conjugate(ADC) and radiopharmaceutical companies approached us with a seemingly simple request: Could we add a C-terminal cysteine to our VHHs?
Tools for ADC drug discovery – screening VHHs with pre-engineered C-terminal cysteine handles
In the fast-paced world of biotechnology, innovation often stems from taking smart, calculated risks. At Isogenica, we are used to running unusual antibody drug discoveryprojects. But sometimes, even we have our doubts. One such moment arose when several Antibody-Drug Conjugate(ADC) and radiopharmaceutical companies approached us with a seemingly simple request: Could we add a C-terminal cysteine to our VHHs?